Fundraising Fox
/Companies
Sign in

Eikonizo Therapeutics

Beverly, US · Founded 2017 · Delaware corporation · 13 employees on LinkedIn · 1 known investors

Find your way into Eikonizo Therapeutics

Sign up to see every warm intro you have to Eikonizo Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Eikonizo Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Eikonizo develops small molecule therapeutics targeting neurodegenerative and cardiorenal diseases. The company is focused on creating novel, disease-modifying treatments to improve patient outcomes.

AI & Machine LearningBiotechDeep TechHealthtechMedical Devices

Founders & leadership

Eikonizo Therapeutics was founded in 2017 by Janice Kranz, PhD and Jacob Hooker, PhD.

JKJanice Kranz, PhD
Janice Kranz, PhDCo-FounderJanice Kranz holds a PhD in biology from Harvard and brings 25 years of experience in startup biotech and nonprofit roles, with expertise in drug discovery research, business development, and securing research funding.
JH
Jacob Hooker, PhDCo-Founder
RL
Rick LundbergPresident, CEO and Director
WS
William ShawNamed on SEC filing
SW
Stacie WeningerNamed on SEC filing
JK
Janice KranzNamed on SEC filing

Board

KKKevin Kinsella
Kevin KinsellaBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$2.4M disclosed across 2 rounds · 2018

▶$371.4KraisedMay 2018 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Janice KranzExecutive Officer, Director
  • Stacie WeningerDirector
  • William ShawExecutive Officer, Director
  • Kevin KinsellaDirector
Offering amount
$841.1K
Amount sold
$371.4K
First sale
May 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedApr 2018 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • William ShawExecutive Officer, Director
  • Kevin KinsellaDirector
  • Stacie WeningerDirector
  • Janice KranzExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
First sale
Mar 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

Eikon TherapeuticsPioneering a drug discovery method based on tracking the movement of individual proteins in living cells.
Actio Biosciences, Inc.Actio is a precision medicine company that translates genetic insights into new therapeutics, developing drugs that target the genes underlying both rare diseases and more prevalent conditions. It focuses on identifying dysregulated gene activity and designing therapies to restore balance and address the root causes of disease.

Companies working in the same space as Eikonizo Therapeutics.

In the news

Eikonizo Therapeutics Receives Equity Investment From Novo Nordiskfinsmes.com · Dec 2024

Frequently asked questions

What does Eikonizo Therapeutics do?
Eikonizo develops small molecule therapeutics targeting neurodegenerative and cardiorenal diseases. The company is focused on creating novel, disease-modifying treatments to improve patient outcomes.
Who founded Eikonizo Therapeutics?
Eikonizo Therapeutics was founded by Janice Kranz, PhD, Jacob Hooker, PhD in 2017.
Who are Eikonizo Therapeutics's investors?
Eikonizo Therapeutics's investors include Mission Biocapital.
How much funding has Eikonizo Therapeutics raised?
Eikonizo Therapeutics has disclosed $2.4M raised across 2 rounds.
Where is Eikonizo Therapeutics headquartered?
Eikonizo Therapeutics is headquartered in Beverly, US.